试验终止ClinicalTrials.gov(美国登记平台)来源日期:2021-06-30
A Study of Venetoclax in Combination With Pomalidomide and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma
编号:NCT03567616登记状态:提前终止企业 / 申办者:AbbVie
药物 / 成分:Venetoclax、Pomalidomide、Dexamethasone
登记的停止原因(原文):Following results of the primary progression-free survival analysis from Study NCT02755597, company-sponsored MM studies were placed on partial clinical hold (PCH). Sponsor did not pursue release of the PCH for this study.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2021-06-30
The Effect of Abobotulinum Toxin A on the Symptoms of Raynaud's Phenomenon
编号:NCT03639766登记状态:提前终止企业 / 申办者:University of Central Florida
药物 / 成分:AbobotulinumtoxinA、Saline solution
登记的停止原因(原文):Time and resource constraints
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2021-06-29
A Phase IV Study in Subjects With Neurogenic Orthostatic Hypotension
编号:NCT00046163登记状态:提前终止企业 / 申办者:Shire
药物 / 成分:midodrine hydrochloride (ProAmatine®)
登记的停止原因(原文):Study was terminated due to poor enrollment
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2021-06-29
Pharmacokinetics of SSP-004184 in the Treatment of Chronic Iron Overload Requiring Chelation Therapy
编号:NCT01604941登记状态:提前终止企业 / 申办者:Shire
药物 / 成分:SPD602
登记的停止原因(原文):This study was terminated due to treatment stop resulting in an inability to draw conclusions from the data. Evaluation of nonclinical rat findings is ongoing.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2021-06-29
Study for Transfusionally Iron Overloaded Children, Adolescents and Adults Using FBS0701 (SSP-004184)
编号:NCT01671111登记状态:提前终止企业 / 申办者:Shire
药物 / 成分:SSP-004184AQ
登记的停止原因(原文):This study was terminated due to treatment stop resulting in an inability to draw conclusions from the data. Evaluation of nonclinical rat findings is ongoing.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2021-06-29
A Phase III Study of Xilonix in Patients With Advanced Colorectal Cancer
编号:NCT01767857登记状态:提前终止企业 / 申办者:Janssen Research & Development, LLC
药物 / 成分:Xilonix、Placebo
登记的停止原因(原文):The study crossed the prospective futility boundary of primary endpoint
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2021-06-29
Fentanyl for Breakthrough Pain in the Emergency Department
编号:NCT01812759登记状态:提前终止企业 / 申办者:M.D. Anderson Cancer Center
药物 / 成分:Fentanyl Nasal Spray、Hydromorphone PCA、Placebo Nasal Spray
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2021-06-29
The Ruxolitinib Versus Best Available Therapy Trial in Patients With High Risk ET in Second Line
编号:NCT02962388登记状态:提前终止企业 / 申办者:French Innovative Leukemia Organisation
药物 / 成分:Anagrelide、Ruxolitinib (JAKAVI®)、IFNα/ PegIFNα
登记的停止原因(原文):not enough recruitment
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2021-06-29
Gallium-68 Prostate Specific Membrane Antigen PET in Diagnosing Patients With Thyroid Cancer
编号:NCT03463889登记状态:提前终止企业 / 申办者:University of California, San Francisco
药物 / 成分:Gallium Ga 68-labeled PSMA-11、Magnetic Resonance Imaging、Positron Emission Tomography (PET)
登记的停止原因(原文):Funding
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2021-06-29
Proactive Protection With Azithromycin and hydroxyChloroquine in Hospitalized Patients With COVID-19
编号:NCT04322396登记状态:提前终止企业 / 申办者:Chronic Obstructive Pulmonary Disease Trial Network, Denmark
药物 / 成分:Azithromycin、Hydroxychloroquine、Placebo oral tablet、Placebo oral tablet
登记的停止原因(原文):Recommended by the DSMB
查看官方原始记录 ↗